Evidence map›Paper›PMID 41001376›Full record

SynthesisFrontiers in medicine2025

Societal participation in the development of orphan drugs: a systematic review.

Sanae Akodad, Delphine De Smedt, Hilde Stevens

Abstract readSystematic Review
In one paragraph

Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sanae AkodadInstitute for Interdisciplinary Innovation in Healthcare (I3h), Faculté de Médecine, Solvay Brussels School of Economics and Management, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Delphine De SmedtDepartment of Public Health and Primary Care, Ghent University, Ghent, Belgium.
Hilde StevensInstitute for Interdisciplinary Innovation in Healthcare (I3h), Faculté de Médecine, Solvay Brussels School of Economics and Management, Université Libre de Bruxelles (ULB), Brussels, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of orphan drugs (ODs) remains constrained by structural barriers, including limited scientific knowledge, high clinical uncertainty, and fragile commercial incentives. In parallel, an alternative ecosystem has emerged in which non-commercial societal actors (patients, advocacy groups, and philanthropic entities) contribute to the design, evaluation, and dissemination of therapies for rare diseases. This systematic review provides the first structured synthesis of empirical evidence on societal participation in OD development, with a specific focus on neuromuscular and neurodegenerative disorders. Twenty-one peer-reviewed studies were included, spanning a range of designs from case reports to stakeholder surveys. A functional typology of societal roles was developed, identifying four primary modalities

Indexed as

clinical trial designhealth technology assessment (HTA)orphan drugspatient advocacy groups (PAGs)rare diseasesregulatory sciencesocietal participation

Identifiers

PMID41001376
PMCPMC12457289

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.